Read + Share
Amedeo Smart
Independent Medical Education
Goldstein LJ, Perez RP, Yardley D, Han LK, et al. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Res 2020;22:4.PMID: 31924241
Email
LinkedIn
Facebook
Twitter
Privacy Policy